In tablet manufacture, phosphatidylserine is handled as a hygroscopic phospholipid with a phosphate ester head group that undergoes acid-catalysed hydrolysis in free water and an unsaturated fatty acid tail that oxidises when exposed to air at elevated temperature. Direct compression of unmilled PS on rotary tablet presses is not robust because the waxy platelet morphology reduces powder flow and produces die-fill variability. The standard process uses dry binder roller compaction: a pre-blend of PS API, microcrystalline cellulose, crospovidone, and colloidal silicon dioxide is passed through a roller compactor with knurled rolls at a specific compaction force between 20 kN/cm and 40 kN/cm and gap 1.0–2.0 mm. Ribbon solid fraction is checked by envelope density and kept between 0.65 and 0.75; lower values generate excessive fines, while higher values reduce tablet compactibility and increase work hardening.

The granulate is milled through a 1.0 mm screen and blended with extragranular croscarmellose sodium and sodium stearyl fumarate for 3–5 min in a bin blender at 10–15 rpm. Compression is performed on a rotary press with a precompression station and 10 mm round standard concave tooling. Compression force is set to achieve tablet hardness 80–120 N and tablet thickness 3.2–3.8 mm. Ejection force is recorded from the press instrumentation; values above 600 N are associated with picking of the lower punch face because the phospholipid acts as a boundary lubricant at high metal contact. Aqueous film coating follows: an HPMC/PEG 3350 dispersion is sprayed in a perforated pan at inlet air 60–70°C, bed temperature 38–42°C, pan speed 4–8 rpm, and spray rate 8–15 g/min/kg. Coating weight gain is set at 3.0–4.0% w/w. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm in 900 mL pH 6.8 phosphate buffer containing 0.5% w/v sodium dodecyl sulfate; the acceptance limit is ≥75% release in 45 min.

Tablet packaging is specified as cold-form aluminium/aluminium blister because PS tablets stored in high-moisture-barrier PVC/PVDC blisters can exceed 3.0% w/w moisture and develop peroxide and acid value excursions. The cold-form laminate has an oxygen transmission rate ≤0.01 cm³/m²/day and a moisture vapour transmission rate ≤0.005 g/m²/day. Finished product water content is tested by USP <921> Method Ia with release limit ≤2.0% w/w; peroxide value is tracked by AOCS Cd 8b-90 against a limit of ≤5.0 meq/kg. Acid value is controlled by ISO 660:2020 with a release limit not exceeding 10.0 mg KOH/g.

What restricts direct encapsulation of PS-phospholipid blends on high-speed capsule fillers?

Phosphatidylserine milled powder is cohesive. Shear-cell testing on a Schulze ring shear tester shows flow function coefficient <4.0; direct fill on high-speed dosator capsule machines results in plug ejection force variation and fill weight RSD above 5%. Dry granulation by roller compaction yielding granulate with D50 150–250 µm and residual moisture ≤1.5% w/w lowers fill weight RSD to ≤2.0% on the same equipment. A tapped bulk density of 0.55–0.65 g/mL, determined by USP <616>, allows filling of size 2 capsules at net fill weights 200–250 mg; a 100 mg PS dose therefore requires one size 2 or size 1 capsule depending on excipient ratio and plug density.

The filling suite is maintained at 20–25°C and ≤35% RH. If PS granulate is left in an open powder bowl beyond 2 h, surface moisture increases to 1.8–2.5% w/w, measured by USP <921> Method Ia, and the resulting plug ejection force on a dosator machine exceeds 10 N. This condition produces capsule shell splitting and powder contamination around the filling ports. Hard gelatin capsules are used when residual granule moisture is below 2.0% w/w; HPMC capsules are selected for higher-moisture granulates because gelatin becomes brittle at low RH. Disintegration is tested under USP <2040> with a limit of ≤15 min in water at 37°C. Dissolution follows USP <711> in pH 6.8 phosphate buffer with 0.5% w/v sodium dodecyl sulfate. Capsule weight uniformity complies with USP <905>; filled capsule moisture is released at ≤2.5% w/w.

When PS is granulated for single-dose stick-pack delivery, the critical process variable is moisture removal under low thermal stress rather than compaction. Wet granulation with a fully aqueous binder solution accelerates hydrolysis of the phosphatidylserine phosphoester bond; a non-aqueous povidone K30 binder in absolute ethanol is used instead. The granulating solvent is sprayed onto a premix of PS, lactose monohydrate, pregelatinised starch, and colloidal silicon dioxide in a top-spray fluid bed or high-shear mixer. Drying is performed under vacuum with product temperature ≤45°C; ethanol is a Class 3 solvent and its final limit is 5000 ppm per USP <467> and ICH Q3C.

Fluid-bed drying in a Glatt GPCG 3.1 or equivalent uses inlet air 45–55°C, product temperature ≤38°C, and final moisture ≤2.0% w/w by USP <731> or USP <921>. Over-drying below 0.5% w/w creates electrostatically charged fines that blind the dust-collector bag and reduce yield; under-drying above 2.5% w/w promotes granule aggregation, acid value rise, and blocking of the 1.0 mm sizing screen. Mixed tocopherols at 0.1–0.3% w/w and ascorbyl palmitate at 0.05–0.1% w/w are co-dissolved in the granulating solvent to keep peroxide value below 5.0 meq/kg during storage.

Stick-pack filling is performed on a vertical form-fill-seal machine with a PET/aluminium/LLDPE laminate. Seal width is set at 8–10 mm; the laminate oxygen transmission rate is ≤0.02 cm³/m²/day. Granule particle size is controlled so 90% passes through a 500 µm sieve, tested by USP <786>. Loss on drying remains ≤2.0% w/w; acid value by ISO 660:2020 is limited to ≤10.0 mg KOH/g.

When Phosphatidylserine Is Processed into Sterile Injectable Lipid Emulsions

Injectable PS is not directly soluble in aqueous vehicles, so the API is incorporated into a submicron lipid emulsion or liposomal carrier. A two-step process is used: a high-shear rotor-stator mixer prepares a coarse pre-emulsion of PS, medium-chain triglycerides, soybean oil, and purified egg lecithin in water-for-injection, followed by high-pressure homogenization at 800–1200 bar for 3–5 passes through a Microfluidizer M-110EH or equivalent. Emulsion temperature is returned to 15–25°C after each pass because turbulent heating above 45°C accelerates peroxide formation in the fatty acid chains.

Droplet size is measured by photon correlation spectroscopy; the target Z-average is 150–250 nm and D95 is <400 nm. The zeta potential of the emulsion in phosphate-buffered saline at pH 6.5 falls between −30 mV and −50 mV, reflecting the anionic PS head group. Divalent cations are a formulation incompatibility: calcium and magnesium ions above approximately 2 mmol/L bind to the PS phosphate group and cause droplet aggregation. Co-infusion with Ringer's lactate or calcium-containing parenteral fluids must be avoided. Terminal autoclaving at 121°C for 15 min can increase lysophosphatidylserine and free fatty acid levels; aseptic filtration through a 0.2 µm polyethersulfone filter is preferred when the emulsion droplet size is sufficiently below the filter cut-off. Container closure integrity is verified by USP <1207> dye ingress or vacuum decay after filling.

Release testing includes USP <788> particulate matter for injections, USP <85> bacterial endotoxin with a limit of ≤1.0 EU/mg where parenteral use is specified, and residual solvent testing under USP <467>. Published data for PS-specific commercial injectable formulations is limited; the processing envelope above is derived from phospholipid-stabilised fat emulsion platform studies and should be verified in preformulation stability chambers under ICH Q1A(R2) photolytic and thermal conditions.

Orodispersible Tablet and Lyophilized Wafer Processing Windows

Orodispersible dosage forms containing PS are constrained by the hydrophobic phospholipid moiety, which slows water ingress and disintegration when PS levels exceed approximately 5% w/w in direct-compression ODTs. A lyophilized wafer route avoids the compaction problem: a suspension of 2–5% w/w PS, gelatin, mannitol, and xanthan gum in purified water is dosed into preformed blister pockets, flash-frozen at −40°C, and dried in a shelf lyophilizer with primary drying shelf temperature −10°C to 0°C for 24–48 h, followed by secondary drying at 20–25°C for 4–8 h. Residual moisture in the lyophilized wafer is controlled to ≤1.0% w/w.

Disintegration of the lyophilized wafer is tested by USP <701> with a target of ≤30 s in 20 mL water at 37°C. The wafer is mechanically fragile and is not compressed; whole-wafer integrity is assessed by visual inspection and high-speed imaging after blister ejection. Published data for PS-specific lyophilized wafer formulations is limited, so collapse temperature and glass transition of the maximally freeze-concentrated phase must be established by freeze-drying microscopy and differential scanning calorimetry before scale-up to production shelves.

Enteric-coated PS multiparticulate systems are manufactured to bypass gastric hydrolysis of the phospholipid head group in low-pH media. PS granules from roller compaction or PS-layered sugar spheres are coated in a fluid-bed Wurster column using a methacrylic acid-ethyl acrylate copolymer dispersion, with triethyl citrate plasticizer at 10–20% of dry polymer weight and talc as anti-tack agent. Coating weight gain is set at 15–25% w/w; lower gains produce gastric acid leakage above 10% after 2 h in 0.1 N HCl, while higher gains can delay release beyond 45 min in the buffer stage.

Coating process parameters are controlled at inlet air 40–50°C, product temperature 28–32°C, and spray rate 2–4 g/min/kg because sustained product temperature above 45°C accelerates PS oxidation. After coating, staged curing at 40°C for 2 h is applied; higher curing temperatures are avoided due to degradation of the phospholipid. Release testing in 0.1 N HCl for 2 h requires ≤10% released; USP <711> Apparatus 2 at 50 rpm in pH 6.8 phosphate buffer with 0.5% w/v sodium dodecyl sulfate then requires ≥75% release within 45 min. Enteric-coated multiparticulates are filled into hard gelatin or HPMC capsules only after residual moisture is confirmed at ≤2.0% w/w, because residual water in the substrate forms pinholes in the enteric membrane during storage.